Arbutus Biopharma Corporation
NASDAQ:ABUS
3.18 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Arbutus Biopharma Corporation |
Symbool | ABUS |
Munteenheid | USD |
Prijs | 3.18 |
Beurswaarde | 602,584,560 |
Dividendpercentage | 0% |
52-weken bereik | 2.21 - 4.72 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. William H. Collier |
Website | https://www.arbutusbio.com |
An error occurred while fetching data.
Over Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)